Vincristine

**Indication**
Kaposi sarcoma of unspecified primary site

**INN**
Vincristine

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

**EML status history**
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

**Tags**
Cancer

**Wikipedia**
Vincristine

**DrugBank**
Vincristine

**Summary of evidence and Expert Committee recommendations**
The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.